Research progress of driving gene and molecular targeting therapy for non-small cell lung cancer / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy
; (12): 381-384, 2020.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-799767
Biblioteca responsável:
WPRO
ABSTRACT
The morbidity and mortality of lung cancer are the highest in China, and the non-small cell lung cancer(NSCLC) is the first one, accounting for about 80% of lung cancer.NSCLC includes squamous cell carcinoma, adenocarcinoma, etc.Because of the slow growth of lung cancer cells and the late diffusion and metastasis, most of the patients were in late stage and lost the best period of surgical treatment.In recent years, molecular targeted therapy for specific genes has become an important strategy for the treatment of NSCLC.Multiple target genes, such as EGFR, KRAS, BRAF and EML4-ALK have been identified.This article reviews the related driving genes and molecular targeted therapy of NSCLC, expecting to be helpful to the individualized treatment of advanced NSCLC patients.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Primary Medicine and Pharmacy
Ano de publicação:
2020
Tipo de documento:
Artigo